Bio

David Greenwald, Ph.D., is a Vice President, Business Development on the Therapeutics team and joined the Firm in 2018. In this role, Dr. Greenwald is responsible for searching for new investment opportunities, supporting business development of Deerfield private portfolio companies, and providing his expertise to Deerfield’s research collaborations and venture creation efforts. Prior to joining Deerfield, Dr. Greenwald was the Director of Business Development at Johns Hopkins Technology Ventures. He was a co-founder and Chief Executive Officer of Relay Technology Management, Inc. and a co-inventor of the Relay Innovation Engine software platform. After Relay was acquired by Decision Resources Group, Dr. Greenwald served as the Director of Client Solutions at Decision Resources Group. Before that, he was an Associate Investigator at the Naval Medical Research Center in Silver Spring, MD, where he worked on developing diagnostic devices for dengue fever. Dr. Greenwald was a Howard Hughes Medical Institute research fellow while earning a B.S. in Cellular Biology and Molecular Genetics from the University of Maryland, College Park and earned his Ph.D. in Genetics from Tufts University. Dr. Greenwald currently serves on the Boards of Jaguar Gene Therapy, Axovia Therapeutics, and Apertura Gene Therapy.